Senseonics (SENS) closed at $9.96 on Oct 6, 2026, down 3.4% on the day. The stock is up 3.4% over the past month, up 87.6% over three months, up 80.4% year to date and up 7.6% over the past year. It trades 6.4% below its 52-week high of $10.64 and 107.9% above its 52-week low of $4.79. The close sits above its 50-day moving average ($8.56) and above its 200-day moving average ($7.01).
Yes — the Oct 6, 2026 close of $9.96 is 42.1% above the 200-day average of $7.01.
SENS closed 6.4% below its 52-week high of $10.64.
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
